Ignite Creation Date:
2024-05-05 @ 11:25 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00031993
Status:
COMPLETED
Last Update Posted:
2013-01-17
First Post:
2002-03-08
Brief Title:
Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Study Overview
Official Title:
A Phase II Evaluation Of OSI-774 NSC 718781 In The Treatment Of Persistent or Recurrent Squamous Cell Carcinoma Of The Cervix
Status:
COMPLETED
Status Verified Date:
2013-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This phase II trial is studying erlotinib to see how well it works in treating patients with persistent or recurrent cancer of the cervix Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor
Detailed Description:
PRIMARY OBJECTIVES
I To evaluate the antitumor cytostatic activity of OSI-774 as measured by the probability of surviving progression-free for at least 6 months in patients with persistent or recurrent squamous cell carcinoma of the cervix
II To determine the nature and degree of toxicity of OSI-774 in this cohort of patients
SECONDARY OBJECTIVES
I To determine the partial and complete response rates in patients with squamous cell carcinoma of the cervix receiving OSI-774
II To determine the duration of progression-free survival and overall survival within this patient population treated with OSI-774
III Assess the effects of prognostic factors initial performance status and age
TERTIARY OBJECTIVES
I To determine epidermal growth factor receptor EGFR and p110 truncated EGFR p110 sEGFR isoform expression levels in primary tumors and from tumor samples obtained pretreatment and following four weeks of therapy to determine tumor response or resistance to OSI-774 inhibition of the EGFR tyrosine kinase
II To correlate EGFR and p110sEGFR expression levels with either MAPK or AKT phosphorylation status in the same tissue samples obtained pretreatment and following four weeks of drug treatment to determine downstream effects with response to OSI-774 inhibition of EGFR
III To determine whether pretreatment serum p110 sEGFR concentrations are a useful prognostic indicator and whether altered andor sEGFR concentrations are useful indicators of therapeutic responsiveness time to progression and overall survival in cervical carcinoma patients
OUTLINE This is a multicenter study
Patients receive oral erlotinib once daily for 4 weeks Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity
Patients are followed every 3 months for 2 years and then every 6 months for 3 years
I To evaluate the antitumor cytostatic activity of OSI-774 as measured by the probability of surviving progression-free for at least 6 months in patients with persistent or recurrent squamous cell carcinoma of the cervix
II To determine the nature and degree of toxicity of OSI-774 in this cohort of patients
SECONDARY OBJECTIVES
I To determine the partial and complete response rates in patients with squamous cell carcinoma of the cervix receiving OSI-774
II To determine the duration of progression-free survival and overall survival within this patient population treated with OSI-774
III Assess the effects of prognostic factors initial performance status and age
TERTIARY OBJECTIVES
I To determine epidermal growth factor receptor EGFR and p110 truncated EGFR p110 sEGFR isoform expression levels in primary tumors and from tumor samples obtained pretreatment and following four weeks of therapy to determine tumor response or resistance to OSI-774 inhibition of the EGFR tyrosine kinase
II To correlate EGFR and p110sEGFR expression levels with either MAPK or AKT phosphorylation status in the same tissue samples obtained pretreatment and following four weeks of drug treatment to determine downstream effects with response to OSI-774 inhibition of EGFR
III To determine whether pretreatment serum p110 sEGFR concentrations are a useful prognostic indicator and whether altered andor sEGFR concentrations are useful indicators of therapeutic responsiveness time to progression and overall survival in cervical carcinoma patients
OUTLINE This is a multicenter study
Patients receive oral erlotinib once daily for 4 weeks Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity
Patients are followed every 3 months for 2 years and then every 6 months for 3 years
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| GOG-0227D | None | None | None |
| U10CA027469 | NIH | None | None |
| CDR0000069247 | REGISTRY | PDQ Physician Data Query | httpsreporternihgovquickSearchU10CA027469 |